Whitehawk Therapeutics, Inc. was formerly known under the corporate name Aadi Bioscience, Inc. prior to undergoing a strategic enterprise relaunch. The corporate renaming and operational evolution marked the company's strategic transition into an advanced oncology therapeutics company focusing heavily on next-generation antibody-drug conjugate development pipelines following its acquisition by Kaken Pharmaceutical Co., Ltd.